An Expanded Access Program for the non-invasive characterization of glioma or treatment related change utilizing Fluorine (F-18) floretyrosine (18F-FET, TLX101-CDx)
The aim of this Expanded Access Program (EAP) is to enable the use of 18F-Floretyrosine with positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance (PET/MR) imaging to non-invasively detect tumor burden
Why this Research Matters
18F-Floretyrosine is being developed as a PET imaging agent for the characterization of glioma or treatment related change
Who can Participate
Adult
All participants must meet all the following criteria prior to receiving 18F-Florestyrosine and undergoing imaging: 1. Written and voluntarily given informed consent. Pediatric patients (<18 years of age) will provide assent along with parental/legal gua
Study ID
Protocol Number: 24-2223
More information available at ClinicalTrials.gov: NCT06743100
Meet the Team
Principal Investigator